Defense Secretary Pete Hegseth announced this week that the Pentagon will begin mandatory annual testosterone screenings for all service members aged 30 and older, marking a significant shift in military health policy that has sparked concern among medical professionals.
The screening will be conducted as part of service members’ regular annual health assessments, with Hegseth saying in a video titled “The High-T Department of War” that the initiative aims to ensure troops “have the right testosterone levels” to operate at their “absolute best.” Service members younger than 30 can voluntarily request testing, and treatment decisions remain voluntary—those found to have testosterone deficiency can choose whether to pursue testosterone replacement therapy (TRT).
Hegseth framed the policy as an investment in military readiness and longevity. “This initiative—it’s not about artificial enhancement, it’s about restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight,” he said in the announcement. One stated objective is to address operator syndrome, which affects special forces such as Delta Force and Navy SEALs and includes low testosterone alongside traumatic brain injury, sleep dysregulation, and other conditions.
However, five of six men’s health experts contacted by Reuters expressed puzzlement at the mandate, saying they were concerned it could lead to unnecessary or even harmful treatment. The American Urological Association and the Endocrine Society both recommend testosterone supplementation only for patients with confirmed deficiency and symptoms such as reduced libido, erectile dysfunction, fatigue, decreased muscle mass, and low bone density—not for asymptomatic screening of entire populations.
Dr. Kevin McVary, a urologist on the medical advisory board of a telehealth platform providing testosterone supplements, stated there is no concrete evidence that screening for low testosterone in all military personnel aged 30 and older would optimize U.S. combat readiness. “We hear from patients that when you treat low T, things like cognitive alertness and stamina improve. But the evidence is not concrete, and it comes from patients who were treated because they were symptomatic,” McVary said.
Medical experts also highlighted significant risks associated with testosterone therapy. All doctors contacted by Reuters mentioned the severe impact on male fertility: testicles can shrink during treatment, and shrinkage is not always reversible. Other documented risks include blood thickening, prostate issues, acne, hair loss, breast tissue growth, and mood volatility. A study led by Dr. Steven Nissen of the Cleveland Clinic found that men on testosterone therapy showed higher rates of atrial arrhythmia—an abnormal heart rhythm—and bone fractures.
Dr. Haleem Mohammed, chief medical officer of Gameday Health, a men’s wellness clinic network, noted that testosterone levels naturally decline with age starting around age 30, but age 30 itself is not an appropriate screening threshold. “There is a population-level decline of 1% per year after ages 30-40 that accelerates as you get older, but the patterns are not the same for all,” Mohammed said. He added that broad screening could identify men with reversible causes of low testosterone—such as being overweight—who could benefit from lifestyle changes rather than medication.
The policy reflects a broader Trump administration push to expand access to testosterone replacement therapy. The Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., proposed earlier this month to loosen FDA restrictions on testosterone therapy, and Kennedy has previously stated he takes testosterone replacements as part of his anti-aging routine. In December 2025, an FDA panel called for regulatory changes to make testosterone therapy more accessible to men with age-related low testosterone.
The Pentagon has not provided detailed guidance on how abnormal test results will be evaluated or whether screenings will apply equally to men and women service members, leaving questions about implementation unresolved.
Sources
- NBC News — Hegseth’s announcement of mandatory screening, policy details, and Trump administration context on testosterone therapy expansion
- The Guardian — Medical expert concerns about the policy, risks of testosterone therapy, and operator syndrome background
- Time Magazine — Urologist perspectives on screening recommendations, TRT risks including infertility and side effects, and medical guidelines
- Reuters — Expert commentary questioning evidence for screening, side effects, and FDA labeling changes
